The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
- Investigator
- Michael R Bubb
- Ages
- 16 Years - N/A
- Sexes
- All